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S
hanks and Brundage offer thought-provoking 
hypotheses about inﬂ   uenza pathogenesis during the 
catastrophic 1918–1919 pandemic (1). Although we 
neither agree nor disagree with their views, its central 
hypothesis of T-cell–mediated immunopathogenesis begs 
examination of past events in light of modern immunologic 
and virologic understanding. We also emphasize that 
effects of the pandemic virus should not be measured only 
by illness and death in 1918–1919, but should also take 
into account disease caused by its descendent seasonal and 
pandemic inﬂ  uenza viruses up to the present (2). Thus, for 
human inﬂ  uenza history to be better understood, it must be 
continually reevaluated.
Speciﬁ  cally, Shanks and Brundage hypothesize that 
high mortality rates in 1918 resulted from immunopathogenic 
effects of cell-mediated immune responses elicited by 
previously circulating inﬂ  uenza viruses. They also suggest 
that clues to immunopathogenic mechanisms are found 
in the unique, well-documented, W-shaped age-speciﬁ  c 
mortality curve of the 1918 pandemic (3) (Figure) in 
which the typical (U-shaped) curve of pandemic inﬂ  uenza, 
featuring mortality rate peaks in young and old persons, 
was augmented by an unprecedented third mortality rate 
peak in persons 20–40 years of age.
A complicating fact about 1918–1919 mortality 
patterns and pathogenesis hypotheses is that for ≈98% of 
infected persons, inﬂ  uenza was clinically unremarkable 
in its traditional signs and symptoms (fever, cough, 
myalgia) and severity (4). Clinical and epidemiologic 
differences were conﬁ  ned to 2 aspects: higher frequency 
of its long-appreciated post-illness complication—
bacterial pneumonia (5)—and an unusual peak in fatal or 
nonfatal pneumonia cases in persons 20–40 years of age. 
In 1918, a higher percentage of persons of all ages, and 
especially those 20–40 years old, experienced inﬂ  uenza 
that led to cases of secondary bacterial pneumonia, which 
were caused by highly prevalent pneumopathogenic 
bacteria (especially pneumococci, streptococci, and 
staphylococci). These bacteria had been continuously 
causing primary pneumonia and pneumonia after 
inﬂ  uenza and other respiratory illnesses, and had long 
been exacting a substantial death toll.
These 1918 postinﬂ   uenza cases of pneumonia 
produced case-fatality rates similar to those of noninﬂ  uenza 
pneumonia caused by the same organisms. Moreover, 
antibacterial vaccines administered in 1918–1919 seem 
to have prevented postinﬂ   uenza deaths (6). Inﬂ  uenza 
mortality rates in 1918–1919 were most strongly associated 
with increased case incidence of, not increased severity 
of, common complicating bacterial pneumonia, and this 
ﬁ   nding was seen especially in persons 20–40 years of 
age. The epidemiology of 1918 inﬂ   uenza mortality is 
predominantly, almost entirely, the epidemiology of a single 
postonset complication: secondary bacterial pneumonia. 
Therefore, pathogenesis theories of severe or fatal 1918 
inﬂ  uenza must account for why the 1918 virus predisposed 
more persons to secondary bacterial pneumonia, and also 
look beyond the virus to address bacterial cofactors. The 
hypotheses of Shanks and Brundage should be considered 
with these observations in mind.
An interesting aspect of the epidemiology of fatal 1918 
inﬂ  uenza is demonstrated by epidemics in US military training 
camps, in which increased mortality rates were strongly 
associated with carriage epidemics of pneumopathogenic 
bacteria (5). An eerily analogous phenomenon had happened 
a year earlier (winter of 1917–1918) in deadly epidemics of 
measles/postmeasles bacterial pneumonia (5). Therefore, 
bacterial carrier status at the time of inﬂ  uenza  virus 
introduction should be considered in interpreting mortality 
rate differences in soldiers and examined with respect to 
epidemiologic variables that could affect carriage (e.g., 
length of service, rural or urban differences, and health 
care worker status). Such simple exposure variables might 
explain at least some of the mortality rate differences pointed 
out by Shanks and Brundage.
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With regard to possible immunoprotection afforded by 
earlier circulating inﬂ  uenza viruses, in our view, the picture 
is not fully interpretable. Epidemiologic information about 
the 1889 global pandemic suggests that the unidentiﬁ  ed 
causative virus was novel in persons born after ≈1830 (4), 
if not before 1830. However, what the 1889 virus was, how 
long it may have circulated after 1889, in what form it may 
have drifted, and what level of population immunity in what 
age groups may have resulted are all speculative. Making 
various assumptions about post-1889 viral circulation 
patterns in an attempt to ﬁ  nd epidemiologic evidence of 
protective or amplifying effects on incidence or mortality 
rates of 1918 inﬂ  uenza has not, to our knowledge, shown 
anything suggestive, let alone deﬁ  nitive.
Given that no age group in 1918 seems to have been 
protected by inﬂ  uenza exposures in 1889, some 1918 data 
are consistent with partial protection in persons >60 years 
of age (i.e., alive during and after the inﬂ  uenza pandemics 
of the 1830s and 1840s), even though the viruses involved 
in these pandemics had no discernible effect on 1889 
inﬂ  uenza incidence (4). To further complicate the picture, 
major antigenic changes in the 1889 pandemic virus around 
1900 have been postulated on the basis of epidemiologic/
serologic evidence, and data from the 1957 (H2N2) and 
1968 (H3N2) pandemics are each consistent with partial 
protection in persons alive during 1889–1918. Taken 
together, this information produces more questions than 
it answers, which suggests that only further virologic or 
serologic evidence based on examination of specimens 
from an earlier era can clarify the situation.
A related issue addressed by Shanks and Brundage 
concerns interpreting data on protection during the fatal 
October–November 1918 fall wave by inﬂ  uenza viruses 
circulating earlier in 1918 (we avoid the term spring 
wave on the grounds described below). In the 9 months 
before the 1918 fall wave, from which inﬂ  uenza (H1N1) 
viruses have been sequenced, 2 seemingly different 
types of inﬂ  uenza phenomena were observed. The ﬁ  rst 
phenomenon was in January–May 1918 when scattered, 
explosive local outbreaks and epidemics of inﬂ  uenza-
like illness occurred in various locations in Europe, and 
episodic outbreaks occurred in several other countries, 
which in virtually all cases showed lower than expected 
mortality rates for inﬂ   uenza. (Shanks and Brundage 
classify this spring activity, along with summer activity, 
as a spring wave.) If this wave was inﬂ  uenza, it was not 
a wave as the term had been used since 1889 to indicate 
global pandemic mortality.
The second phenomenon was a wave of moderate 
mortality rates that occurred not in the spring of 1918, but 
in the summer (July–August), mostly in a few countries in 
northern Europe. This summer wave seems consistent with a 
ﬁ  rst major occurrence of the 1918 virus (H1N1), which may 
have found a tenuous foothold in the normally unfavorable 
summer months, predominantly in northern climes where 
temperature and humidity might be less restrictive of virus 
circulation. If this wave was the 1918 pandemic virus, 
simple arithmetic dictates that to have reached moderate 
explosiveness by July it must have been circulating for at 
least many weeks beforehand (7). Prepandemic circulation 
of virus (H1N1) in early 1918 could have caused at least 
some circumscribed outbreaks that elicited protection. 
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Figure. Combined inﬂ   uenza plus pneumonia (P&I) age-speciﬁ  c 
incidence, mortality, and case-fatality rates, per 1,000 persons/age 
group, US Public Health Service house-to-house surveys, 8 states, 
1918, and US Public Health Service surveys during 1928–1929. 
A) P&I incidence for 1918; B) mortality rate for 1918 (ill and well 
persons combined); C) P&I case-fatality rates for 1918 (solid line) 
compared with a more typical curve of age-speciﬁ  c inﬂ  uenza case-
fatality rates (dotted line) from 1928–1929. Reprinted from (3).However, if all winter–spring prepandemic 1918 activity 
had been caused by the pandemic virus, we are left with 
the conundrum of why it did not become pandemic then, 
when environmental circumstances were seemingly more 
favorable, and when it was being locally transmitted within 
the war zone in Europe at more explosive levels than the fall 
wave pandemic virus would later be. We must also explain 
the frustratingly contradictory protection data from spring 
or summer inﬂ  uenza-like illness during the fall occurrence 
of inﬂ  uenza.
Astute observers of the time considered the 1918 
protection data uninterpretable (8). Because inﬂ  uenza 
viruses of different subtypes are now understood to protect 
against each other for prolonged periods (e.g., H1N1 
against H2N2 and H2N2 against H3N2), interpreting 1918 
protection data has become even more problematic. One or 
more viruses unrelated to the fall wave virus (H1N1) (e.g., 
an 1889 viral descendant) may have caused at least some 
of the observed protection and nonprotection phenomena 
in 1918. Less plausibly, the pandemic virus could have 
lost transmissibility while gaining pathogenicity after early 
1918. However, in the absence of virologic evidence, the 
identity of early 1918 viruses that may have caused or 
failed to cause protection remains speculative.
Finally, despite whatever degree of immunopatho-
genesis or immunoprotection may have occurred in 
1918, we see no particular reason to focus hypotheses on 
T-cell immunity over immunity conferred by antibody to 
viral antigens. The extremely high 1918 inﬂ  uenza infant 
mortality rate cannot easily be linked to cell-mediated 
immunity because infant T cells would presumably 
have never been exposed to inﬂ  uenza viruses. It is also 
noteworthy that mortality rates across the entire 1918 age 
spectrum were higher than in any other year between 1889 
and the present time. In looking at the W-shaped mortality 
curve, we believe that the ﬁ  ndings are striking for persons 
≈5–14 years of age, the age range of persons with the 
lowest mortality rates in virtually all inﬂ  uenza pandemics 
and epidemics studied to date. In 1918, this age group 
appears to have had an ≈4-fold higher mortality rate than 
in 1889, conceivably indicating inherent viral virulence or, 
more correctly, viral–bacterial copathogenicity because 
most of the relatively few deaths in this age group seem 
also attributable to secondary bacterial pneumonia.
Although it is intriguing to speculate about the role 
of severe and fatal primary viral pneumonia, we are 
unaware of data suggesting that primary viral or viral 
immunopathogenic mechanisms accounted for high 
mortality rates in any 1918 age group; results of reported 
experimental animal studies are of uncertain relevance for 
humans. Almost all of the tens of thousands of autopsies 
reported in 1918 indicated classic bacterial pneumonia 
as the most prominent feature, which was different in 
frequency, but not in kind, from the familiar cases of 
pneumonia seen year in and year out, before and after 
1918 (5,7). The data appear most consistent with some 
unidentiﬁ  ed property of the 1918 virus (e.g., respiratory 
cell cytopathicity) that potentiated pneumonia with 
common bacteria carried in the upper respiratory tract (5). 
The cause of the middle peak of the W-shaped mortality 
curve remains a fascinating mystery that so far seems 
inexplicable by any hypothesis.
In summary, Shanks and Brundage have addressed 
3 major mysteries of the 1918 inﬂ  uenza pandemic: high 
mortality rates/unexplained pathogenesis, unexplained age-
speciﬁ  c mortality rate patterns, and evidence for wave-to-
wave protection, with a unifying hypothesis. In our view, 
they justiﬁ  ably point out that highly inconsistent wave-
to-wave protection data from different 1918 observers 
represent essential clues to what happened 94 years ago. 
However, these clues have not yet led to satisfactory 
answers. They also draw attention to the W-shaped age-
speciﬁ  c mortality curve, still unexplained we would argue, 
and hypothesize that it, as well as disease pathogenesis and 
protection, results from cell-mediated immune responses. 
Although we are not fully persuaded by all aspects of this 
hypothesis, it does suggest avenues for experimental and 
perhaps serologic and immunologic research. It should also 
stimulate us to rethink old mysteries in light of modern and 
evolving understanding of inﬂ  uenza. Questions about 1918 
persist, and critical pieces of the puzzle, in our view, are 
still missing.
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